Adc Therapeutics SA
ADCTHealthcare·Drug Manufacturers - Specialty & Generic·Switzerland·Micro·NYSE·Nov 13 • 7:12 AM ET
1.40-0.01 (-0.71%)
2026-11-13 13:13 CET
Market cap
$178.73M
Revenue, TTM
84.87 USD m
Net income, TTM
-81.25 USD m
Free cash flow, TTM
-99.03 USD m
EPS diluted, TTM
-0.53
Price
ADCT against its 20, 50 and 200-day averagesPatternshover a marker to name it
71.9% under the 52-week high of 4.98 on 11 Mar 2026. 52-week low 0.78 on 8 Jun 2026. Last 15 sessions, 33.2% high to low
Volume 0.00× normal · the line is the 50-bar volume average
Setup. RS line 12
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 2 of 5 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 1 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%) — not on the tape: Return on Equity: Over +15%
Quality 1 of 5 — fails: Net Profit Margin: High (>20%) — not on the tape: Return on Equity: Over +15%; Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
ADCT52-week range, 15% of the way up
0.784.98
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
| Index | RUT |
|---|---|
| Employees | 193 |
| IPO | May 15, 2020 |
| Beta | 1.80 |
| ATR, 14d | 0.16 |
| Rel volume | 0.00 |
| Short float | 6.49% |
| Insider own | 22.42% |
| Inst own | 62.21% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $178.73M |
| Enterprise Value | 105.63M |
| Income | -81.25M |
| Sales | 84.87M |
| Book / share | -1.95 |
| Cash / share | 1.48 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 193 |
| IPO | May 15, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 2.11 |
| Price / book | - |
| Price / cash | 0.94 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 1.24 |
| Quick Ratio | 2.98 |
| Current Ratio | 3.05 |
| Debt / equity | - |
| Long-term debt / equity | - |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.53 |
|---|---|
| Earnings next year | -0.64 |
| Earnings next quarter | -0.17 |
| Earnings this year | 37.72% |
| Earnings next year | 7.89% |
| Earnings growth, 5 years | 29.86% |
| Past earnings growth | 17.66% 21.50% |
| Past sales growth | -27.09% - |
| Earnings vs last year | 63.71% |
| Sales vs last year | 12.85% |
| Earnings vs last quarter | 45.77% |
| Sales vs last quarter | 32.20% |
| Earnings | Nov 09 BMO |
| Surprise | 24.71% 16.13% |
Ownership
| Insiders own | 22.42% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 62.21% |
| Institution trades | -0.85% |
| Return on assets | -29.78% |
| Return on equity | - |
| Return on capital | - |
| Gross Margin | 88.37% |
| Operating margin | -95.17% |
| Profit Margin | -95.73% |
| 20-day average | -9.27% |
| 50-day average | 0.63% |
| 200-day average | -41.11% |
Technical
| Shares out | 127.74M |
|---|---|
| Shares floating | 99.04M |
| Short / float | 6.49% |
| Short ratio | 3.84 |
| Short interest | 6.43M |
| 52-week high | 4.98 -71.9% |
| 52-week low | 0.78 +79.5% |
| Volatility | 14.75% 10.54% |
| Average range | 0.16 |
| Strength index | 45.54 |
| Market sensitivity | 1.80 |
| Relative volume | 0.00 |
| Avg Volume | 1.67M |
| Volume | 51 |
Performance
| Perf Week | -11.39% |
|---|---|
| Perf Month | -6.04% |
| Perf Quarter | 27.27% |
| Perf Half Y | -56.92% |
| Perf YTD | -60.34% |
| Perf Year | -65.43% |
| Perf 3Y | 180.00% |
| Perf 5Y | -94.71% |
| Perf 10Y | - |
| Recommendation | 2.20 |
| Target Price | 2.62 |
| Prev Close | 1.41 |
| Price | 1.40 |
| Change % | -0.71% |
Analyst ratings
latest 10 of 19| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jun 08, 2026 | Downgrade | H.C. Wainwright | Buy → Neutral | ||
| Jun 04, 2026 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform | $2 | +42.9% |
| Nov 08, 2024 | Initiated | Stephens | Overweight | $6 | +328.6% |
| May 30, 2024 | Initiated | Cantor Fitzgerald | Overweight | ||
| Mar 28, 2024 | Initiated | Guggenheim | Buy | $11 | +685.7% |
| Aug 10, 2023 | Upgrade | JP Morgan | Underweight → Neutral | ||
| Apr 24, 2023 | Downgrade | BofA Securities | Neutral → Underperform | $7 → $2 | +42.9% |
| Dec 06, 2022 | Initiated | CapitalOne | Overweight | $12 | +757.1% |
| Nov 09, 2022 | Downgrade | BofA Securities | Buy → Neutral | $14 → $7 | +400.0% |
| Sep 21, 2022 | Initiated | JP Morgan | Overweight | $5 | +257.1% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| STRO | Sutro Biopharma Inc | 159.01M |
| PYXS | Pyxis Oncology Inc | 188.98M |
| AUTL | Autolus Therapeutics plc ADR | 316.94M |
| ZYME | Zymeworks BC Inc | 1.84B |
| CTMX | CytomX Therapeutics Inc | 444.73M |
| GMAB | Genmab ADR | 31.56B |
| CMPX | Compass Therapeutics Inc | 147.65M |
| ONC | BeOne Medicines Ltd ADR | 43.79B |
| GERN | Geron Corp | 625.42M |
| KURA | Kura Oncology Inc | 689.09M |
Insider trading
6 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner | Apr 02 '26 | Sale | 3.28 | 2,634,506 | 8,638,545 | 12,666,731 | Apr 02 09:00 PM |
| Redmile Group, LLC | 10% Owner | Apr 02 '26 | Sale | 3.28 | 2,529,491 | 8,294,201 | 10,265,297 | Apr 02 09:00 PM |
| Redmile Group, LLC | 10% Owner | Mar 31 '26 | Sale | 3.75 | 196,229 | 736,251 | 15,470,502 | Apr 02 09:00 PM |
| Redmile Group, LLC | 10% Owner | Mar 31 '26 | Sale | 3.75 | 188,407 | 706,903 | 12,957,305 | Apr 02 09:00 PM |
| Redmile Group, LLC | 10% Owner | Apr 01 '26 | Sale | 3.80 | 169,265 | 643,038 | 15,301,237 | Apr 02 09:00 PM |
| Redmile Group, LLC | 10% Owner | Apr 01 '26 | Sale | 3.80 | 162,517 | 617,402 | 12,794,788 | Apr 02 09:00 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| GWX | State Street SPDR S&P International Small Cap ETF | AUM: 909.75M |
| VTWV | Vanguard Russell 2000 Value Index ETF | AUM: 1.29B |
| RSSL | Global X Russell 2000 ETF | AUM: 1.44B |
| IWV | iShares Russell 3000 ETF | AUM: 20.58B |
News
latest 14 of 200- ADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire) +5.70%
- ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA Clinical Program (PR Newswire) +10.97%
- ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
- ADC Therapeutics Announces New Employee Inducement Grant (PR Newswire)
- ADC Therapeutics Must Show Lotus 7 Can Carry The Story After Lotus 5's FDA Setback (Earnings Whispers)
- ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 (PR Newswire)
- ADC Therapeutics Announces ZYNLONTA Updates in Japan (PR Newswire) -8.02%
- ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements (PR Newswire) +11.97%
- These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch) +6.67% +9.82%
- ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference (PR Newswire)
- ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... (GuruFocus.com) -14.63%
- ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates (PR Newswire)
- Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside (GuruFocus.com)
- ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 (PR Newswire) +5.61%
Quarterly earnings
2026Q3 EPS -0.160 beat -0.213, from -0.300 a year earlier. Sales 21.72 beat 18.70, from 16.43 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-09 08:30 | -0.160 | -0.213 | -0.160 | 21.72 | 18.70 | EPS -24.7% · sales +16.1% | vs 2025Q3, year-ago quarter · EPS -46.7% · sales +32.2% | 4 | Open +4.43% vs SPY +0.91%. Close +5.70% vs SPY +2.37% |
| 2026Q2ended 2026-06-30 | 2026-08-13 08:30 | -0.110 | -0.216 | -0.107 | 19.25 | 18.89 | EPS -49.1% · sales +1.9% | vs 2025Q2, year-ago quarter · EPS -78.0% · sales +2.2% | 5 | Open -13.01% vs SPY +0.31%. Close -14.63% vs SPY +0.70% |
| 2026Q1ended 2026-03-31 | 2026-05-04 08:30 | -0.210 | -0.202 | -0.214 | 20.85 | 19.99 | EPS +4.1% · sales +4.3% | vs 2025Q1, year-ago quarter · EPS -41.7% · sales -9.5% | 6 | Open -6.53% vs SPY -0.08%. Close -3.92% vs SPY -0.37% |
| 2025Q4ended 2025-12-31 | 2026-03-10 08:30 | -0.040 | -0.268 | -0.043 | 23.06 | 22.30 | EPS -85.1% · sales +3.4% | vs 2024Q4, year-ago quarter · EPS -86.2% · sales +36.4% | 6 | Open +7.33% vs SPY -0.08%. Close +13.48% vs SPY -0.16% |
| 2025Q3ended 2025-09-30 | 2025-11-10 08:30 | -0.300 | -0.363 | -0.300 | 16.43 | 16.79 | EPS -17.4% · sales -2.2% | vs 2024Q3, year-ago quarter · EPS -28.6% · sales -11.0% | 6 | Open -0.25% vs SPY +0.93%. Close +4.21% vs SPY +1.56% |
| 2025Q2ended 2025-06-30 | 2025-08-12 08:30 | -0.500 | -0.492 | -0.498 | 18.84 | 17.86 | EPS +1.6% · sales +5.5% | vs 2024Q2, year-ago quarter · EPS +31.6% · sales +8.2% | 5 | Open +0.37% vs SPY +0.37%. Close +9.70% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-14 08:30 | -0.360 | -0.403 | -0.360 | 23.03 | 17.71 | EPS -10.7% · sales +30.1% | vs 2024Q1, year-ago quarter · EPS -35.7% · sales +27.6% | 6 | Open +9.85% vs SPY +0.17%. Close +37.12% vs SPY +0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-27 08:30 | -0.290 | -0.412 | -0.292 | 16.91 | 19.01 | EPS -29.6% · sales -11.0% | vs 2023Q4, year-ago quarter · EPS -71.8% · sales +0.7% | 6 | Open -0.63% vs SPY -0.25%. Close -3.80% vs SPY -0.27% |
| 2024Q3ended 2024-09-30 | 2024-11-07 08:30 | -0.420 | -0.395 | -0.420 | 18.46 | 18.43 | EPS +6.3% · sales +0.2% | vs 2023Q3, year-ago quarter · EPS -27.6% · sales +27.4% | 6 | Open +0.31% vs SPY +0.35%. Close -8.44% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-06 08:30 | -0.380 | -0.457 | -0.382 | 17.41 | 18.89 | EPS -16.9% · sales -7.8% | vs 2023Q2, year-ago quarter · EPS -34.5% · sales -9.7% | 7 | Open +0.35% vs SPY +0.36%. Close +1.74% vs SPY +0.92% |
| 2024Q1ended 2024-03-31 | 2024-05-06 08:30 | -0.560 | -0.556 | -0.565 | 18.05 | 18.04 | EPS +0.8% · sales +0.0% | vs 2023Q1, year-ago quarter · EPS -24.3% · sales -4.7% | 6 | Open -1.63% vs SPY +0.48%. Close -9.18% vs SPY +1.03% |
| 2023Q4ended 2023-12-31 | 2024-03-13 08:30 | -1.030 | -0.502 | -1.033 | 16.79 | 15.31 | EPS +105.1% · sales +9.6% | vs 2022Q4, year-ago quarter · EPS +243.3% · sales -75.9% | 5 | Open -3.82% vs SPY +0.06%. Close -12.36% vs SPY -0.16% |
| 2023Q3ended 2023-09-30 | 2023-11-07 08:30 | -0.580 | -0.634 | -0.581 | 14.49 | 15.15 | EPS -8.5% · sales -4.4% | vs 2022Q3, year-ago quarter · EPS -10.8% · sales -81.0% | 5 | - |
| 2023Q2ended 2023-06-30 | 2023-08-08 08:30 | -0.580 | -0.700 | -0.578 | 19.28 | 20.25 | EPS -17.1% · sales -4.8% | vs 2022Q2, year-ago quarter · EPS -31.0% · sales +11.5% | 6 | - |
| 2023Q1ended 2023-03-31 | 2023-05-09 08:30 | -0.740 | -0.020 | -0.735 | 18.95 | 20.12 | EPS +3600.0% · sales -5.8% | vs 2022Q1, year-ago quarter · EPS +236.4% · sales -59.2% | 1 EPS · 6 sales | - |
| 2022Q4ended 2022-12-31 | 2023-02-28 08:30 | -0.300 | -0.483 | -0.300 | 69.80 | 39.38 | EPS -37.9% · sales +77.2% | vs 2021Q4, year-ago quarter · EPS -33.3% · sales +310.3% | 3 EPS · 6 sales | - |
Annual earnings
2025FY EPS -1.120 beat -1.405, from -1.620 a year earlier. Sales 81.36 beat 80.57, from 70.84 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.201 | - | - | 308.31 | 6.96 |
| 2029FYestimate | - | 0.049 | - | - | 272.18 | 28.51 |
| 2028FYestimate | - | -0.387 | - | - | 191.64 | - |
| 2027FYestimate | - | -0.643 | - | - | 96.96 | - |
| 2026FYestimate | - | -0.698 | - | - | 80.45 | - |
| 2025FY | -1.120 | -1.405 | -1.120 | 81.36 | 80.57 | - |
| 2024FY | -1.620 | -1.690 | -1.625 | 70.84 | 72.66 | - |
| 2023FY | -2.940 | -2.394 | -2.938 | 69.56 | 68.07 | - |
| 2022FY | -1.990 | -2.070 | -2.011 | 209.91 | 187.67 | - |
| 2021FY | -3.000 | -3.441 | -2.997 | 33.92 | 33.01 | - |
| 2020FY | -2.690 | -3.528 | -3.765 | 0.00 | 1.29 | - |
Quarterly results
2026Q3 revenue 21.72, from 16.43 a year earlier. Operating margin -66.3%, from -186.18% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.70 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-09 | -0.70 | -7.3% |
| 2026Q4 | E | per share | 2026-11-09 | -0.17 | -11.8% |
| 2026FY | R | per share | 2026-11-09 | -0.70 | -7.3% |
| 2026Q4 | R | per share | 2026-11-09 | -0.17 | -11.8% |
| 2026FY | S | per share | 2026-11-09 | 80.45 | +1.1% |
| 2026Q4 | S | per share | 2026-11-09 | 22.00 | +0.2% |
| 2026Q3 | S | per share | 2026-11-04 | 18.70 | +0.0% |
| 2026Q3 | E | per share | 2026-10-27 | -0.21 | -1.2% |
| 2026Q3 | R | per share | 2026-10-27 | -0.21 | -1.2% |
| 2026Q2 | E | per share | 2026-08-13 | -0.14 | -34.3% |
| 2026Q2 | R | per share | 2026-08-13 | -0.14 | -34.3% |
| 2026Q2 | S | per share | 2026-08-13 | 19.30 | +2.2% |
| 2026Q1 | E | per share | 2026-03-20 | -0.20 | -1.1% |
| 2026Q1 | R | per share | 2026-03-20 | -0.20 | -1.1% |
| 2026Q1 | S | per share | 2026-03-20 | 19.99 | -0.2% |
| 2025FY | E | per share | 2026-03-02 | -1.41 | +1.0% |
| 2025Q4 | E | per share | 2026-03-02 | -0.27 | -1.3% |
| 2025FY | R | per share | 2026-03-02 | -1.41 | +1.0% |
| 2025Q4 | R | per share | 2026-03-02 | -0.27 | -1.3% |
| 2025FY | S | per share | 2026-03-02 | 80.57 | +0.9% |
| 2025Q4 | S | per share | 2026-03-02 | 22.30 | +3.4% |
| 2025Q3 | E | per share | 2025-11-03 | -0.36 | +0.4% |
| 2025Q3 | R | per share | 2025-11-03 | -0.36 | +0.4% |
| 2025Q3 | S | per share | 2025-11-03 | 16.79 | -1.7% |
| 2025Q2 | E | per share | 2025-08-04 | -0.49 | +3.8% |
| 2025Q2 | R | per share | 2025-08-04 | -0.49 | +3.8% |
| 2025Q2 | S | per share | 2025-07-29 | 17.86 | 0.0% |
| 2025Q1 | E | per share | 2025-04-02 | -0.40 | +0.4% |
| 2025Q1 | R | per share | 2025-04-02 | -0.40 | +0.4% |
| 2025Q1 | S | per share | 2025-04-02 | 17.71 | -1.0% |
| 2024Q4 | E | per share | 2025-03-24 | -0.41 | +1.4% |
| 2024Q4 | R | per share | 2025-03-24 | -0.41 | +1.4% |
| 2024FY | S | per share | 2025-03-24 | 72.66 | 0.0% |
| 2024Q4 | S | per share | 2025-03-24 | 19.01 | -0.3% |
| 2024FY | E | per share | 2025-03-21 | -1.67 | -1.3% |
| 2024FY | R | per share | 2025-03-21 | -1.67 | -1.3% |
| 2024Q3 | E | per share | 2024-10-31 | -0.40 | +3.2% |
| 2024Q3 | R | per share | 2024-10-31 | -0.40 | +3.2% |
| 2024Q3 | S | per share | 2024-10-31 | 18.43 | -0.1% |
| 2024Q2 | E | per share | 2024-07-30 | -0.46 | +2.6% |
| 2024Q2 | R | per share | 2024-07-30 | -0.46 | +2.6% |
| 2024Q2 | S | per share | 2024-07-30 | 18.89 | +0.2% |
| 2024Q1 | E | per share | 2024-05-01 | -0.56 | -0.1% |
| 2024Q1 | R | per share | 2024-05-01 | -0.56 | -0.1% |
| 2024Q1 | S | per share | 2024-05-01 | 18.04 | -0.5% |
| 2023FY | S | per share | 2024-03-05 | 68.07 | 0.0% |
| 2023FY | E | per share | 2024-02-15 | -2.39 | +1.9% |
| 2023FY | R | per share | 2024-02-15 | -2.39 | +1.9% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -1.304 | -1.787 | -1.742 | -3.765 | -2.997 | -2.011 | -2.938 | -1.625 | -1.122 | -0.5262 | - |
| Sales USD millions | 2 | 1 | 2 | 0 | 34 | 210 | 70 | 71 | 81 | 85 | - |
| Shares million shares | 69 | 69 | 67 | 77 | 77 | 81 | 82 | 99 | 126 | - | 128 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.42 | -0.292 | -0.36 | -0.498 | -0.3 | -0.043 | -0.214 | -0.107 | -0.163 |
| Sales USD millions | 18 | 17 | 23 | 19 | 16 | 23 | 21 | 19 | 22 |
| Shares million shares | 97 | 99 | 99 | 112 | 113 | 126 | 127 | 127 | 128 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 84.87 | 81.36+14.9% | 70.84+1.8% | 69.56-66.9% | 209.91+518.8% | 33.92 | 0.00-100.0% | 2.34+105.3% | 1.14 |
| Cost of Goods Sold Incl. D&A | 9.87 | 7.67-16.9% | 9.23+59.1% | 5.80+1.9% | 5.69+43.3% | 3.97+101.5% | 1.97 | - | - |
| Gross Profit | 75.00 | 73.68+19.6% | 61.61-3.4% | 63.76-68.8% | 204.22+582.1% | 29.94 | -1.97 | - | - |
| Selling, General and Administrative Excl. Other | 155.77 | 182.06-5.3% | 192.27-15.7% | 228.14-29.9% | 325.40+11.7% | 291.30+34.6% | 216.49+82.8% | 118.44-6.3% | 126.34 |
| Research and Development | 70.27 | 104.01-5.1% | 109.63-13.8% | 127.13-31.8% | 186.46+19.9% | 155.53+11.3% | 139.71+33.5% | 104.62-11.1% | 117.74 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -80.77 | -108.38 | -130.65 | -164.38 | -121.18 | -261.35 | -218.46 | -117.74 | -125.71 |
| Interest Expense | 52.60 | 51.63+2.8% | 50.21+8.4% | 46.33+26.1% | 36.73+98.6% | 18.49+275.1% | 4.93+2981.2% | 0.16 | 0.00 |
| Unusual Expense | -34.80 | -9.09 | -11.47 | -3.86 | -8.28 | -34.89-173.9% | 47.20 | 0.00-100.0% | 0.23 |
| Net Income Before Taxes | -81.76 | -142.78 | -157.20 | -196.35 | -147.17 | -244.83 | -270.33 | -115.90 | -122.87 |
| Income Taxes | -0.51 | -0.16 | -0.90-102.4% | 38.17 | -0.13 | -21.48-6609.1% | 0.33-43.1% | 0.58+163.6% | 0.22 |
| Consolidated Net Income | -81.25 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | -123.10 |
| Net Income From Continuing Operations | -81.25 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | -123.10 |
| Net Income | -81.25 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | -123.10 |
| EPS (Recurring) per share | -0.68 | -1.17 | -1.71 | -2.97 | -2.08 | -3.32 | -3.26 | -1.74 | -1.78 |
| EPS (Basic, Before Extraordinaries) per share | -0.53 | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 | -3.77 | -1.74 | -1.79 |
| EPS (Diluted) per share | -0.53 | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 | -3.77 | -1.74 | -1.79 |
| EBITDA | -80.54 | -106.50 | -127.38 | -161.11 | -118.79 | -258.72 | -216.49 | -116.10 | -125.20 |
| Non-Operating Income (Expense) | 16.82 | 8.14-33.2% | 12.19+16.2% | 10.49+326.4% | 2.46+1950.0% | 0.12-53.8% | 0.26-87.0% | 2.00-34.9% | 3.07 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 12.92 | 6.65+28.1% | 5.19-51.3% | 10.66-72.6% | 38.96-24.4% | 51.51+40.9% | 36.56+3873.9% | 0.92+135.9% | 0.39 |
| Price To Sales Ratio ratio | 2.23 | 5.51 | 2.73 | 1.95 | 1.43 | 45.71 | - | - | - |
| Gross Margin % | 88.37 | 90.57 | 86.98 | 91.67 | 97.29 | 88.29 | - | - | - |
| Operating Margin % | -95.17 | -133.21 | -184.44 | -236.32 | -57.73 | -770.57 | - | -5,031.79 | -11,027.54 |
| Net Margin % | -95.73 | -175.31 | -222.83 | -345.11 | -74.86 | -678.20 | - | -4,977.95 | -10,797.89 |
| Shares Outstanding million shares | 127.74 | 125.75+27.2% | 98.86+20.1% | 82.29+2.0% | 80.64+5.0% | 76.81+0.1% | 76.72+14.7% | 66.87-2.9% | 68.89 |
| Market Capitalization | 180.01 | 180.01-6.4% | 192.41+43.7% | 133.87-54.7% | 295.34-80.9% | 1,549.88-36.9% | 2,455.68+0.2% | 2,451.84 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.72+32.2% | 19.25+2.2% | 20.85-9.5% | 23.06+36.4% | 16.43-11.0% | 18.84+8.2% | 23.03+27.6% | 16.91+0.7% |
| Cost of Goods Sold Incl. D&A | 1.98+50.0% | 2.35+39.9% | 3.73+30.4% | 1.81-16.2% | 1.32-20.0% | 1.68-18.4% | 2.86-14.6% | 2.16+77.0% |
| Gross Profit | 19.74+30.7% | 16.90-1.5% | 17.12-15.1% | 21.25+44.1% | 15.10-10.2% | 17.16+11.7% | 20.17+37.2% | 14.75-5.3% |
| Selling, General and Administrative Excl. Other | 34.15-25.3% | 39.60-17.9% | 42.37-12.9% | 39.66-15.9% | 45.70-12.8% | 48.22+8.6% | 48.64+0.7% | 47.18-12.5% |
| Research and Development | 14.74-45.0% | 17.33-42.4% | 19.88-31.3% | 18.33-32.4% | 26.80-17.5% | 30.09+23.8% | 28.93+12.4% | 27.10-10.6% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -14.41 | -22.70 | -25.25 | -18.41 | -30.59 | -31.06 | -28.46 | -32.44 |
| Interest Expense | 13.73+2.5% | 13.51+3.9% | 12.35+1.0% | 13.01+9.1% | 13.39+2.1% | 13.00+2.5% | 12.23-2.2% | 11.92-7.7% |
| Unusual Expense | 1.16+205.3% | -11.69-189.3% | -2.23 | -22.04 | 0.38 | 13.09 | 0.00-100.0% | -10.45-749.1% |
| Net Income Before Taxes | -25.30 | -16.53 | -32.97 | -6.96 | -41.23 | -55.87 | -38.72 | -31.28 |
| Income Taxes | 0.00 | 0.04-94.8% | 0.00 | -0.55 | -0.27 | 0.77 | -0.12 | -0.55-101.3% |
| Consolidated Net Income | -25.30 | -16.57 | -32.97 | -6.41 | -40.97 | -56.65 | -38.60 | -30.73 |
| Net Income From Continuing Operations | -25.30 | -16.57 | -32.97 | -6.41 | -40.97 | -56.65 | -38.60 | -30.73 |
| Net Income | -25.30 | -16.57 | -32.97 | -6.41 | -40.97 | -56.65 | -38.60 | -30.73 |
| EPS (Recurring) per share | -0.16 | -0.16 | -0.22 | -0.15 | -0.30 | -0.42 | -0.36 | -0.36 |
| EPS (Basic, Before Extraordinaries) per share | -0.16 | -0.11 | -0.21 | -0.04 | -0.30 | -0.50 | -0.36 | -0.29 |
| EPS (Diluted) per share | -0.16 | -0.11 | -0.21 | -0.04 | -0.30 | -0.50 | -0.36 | -0.29 |
| EBITDA | -14.41 | -22.70 | -25.13 | -18.30 | -30.47 | -30.22 | -27.66 | -31.64 |
| Non-Operating Income (Expense) | 4.00+27.8% | 7.99+529.1% | 2.40+21.2% | 2.43-7.6% | 3.13-14.7% | 1.27-63.3% | 1.98-37.5% | 2.63-79.8% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 4.09+158.9% | 4.77+233.6% | 2.54+33.0% | 1.53-30.5% | 1.58-28.8% | 1.43-8.9% | 1.91+1491.7% | 2.20+25.7% |
| Price To Sales Ratio ratio | 2.23 | 2.08 | 7.30 | 6.52 | 7.26 | 3.95 | 1.99 | 2.96 |
| Gross Margin % | 90.88 | 87.80 | 82.12 | 92.14 | 91.95 | 91.10 | 87.57 | 87.20 |
| Operating Margin % | -66.37 | -117.94 | -121.07 | -79.85 | -186.23 | -164.85 | -123.58 | -191.82 |
| Net Margin % | -116.52 | -86.06 | -158.11 | -27.80 | -249.38 | -300.68 | -167.59 | -181.71 |
| Shares Outstanding million shares | 127.74+13.4% | 127.44+13.3% | 127.17+28.2% | 125.75+27.2% | 112.63+16.5% | 112.50+16.6% | 99.18+19.8% | 98.86+20.1% |
| Market Capitalization | 180.01-60.0% | 136.09-48.8% | 476.42+241.0% | 437.29+127.3% | 450.00+47.7% | 265.80-12.6% | 139.71-62.3% | 192.41+43.7% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 261.34+4.2% | 250.87-10.0% | 278.60-14.7% | 326.44-30.0% | 466.54+6.2% | 439.19+280.1% | 115.55-16.8% | 138.81-47.2% | 262.75 |
| Short Term Receivables | 29.12+43.3% | 20.32-19.3% | 25.18-65.5% | 72.97+134.9% | 31.06+1054.6% | 2.69+35.2% | 1.99+16.4% | 1.71-11.4% | 1.93 |
| Inventories | 4.18-77.3% | 18.39+13.7% | 16.18+34.1% | 12.07+8.5% | 11.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 11.70-34.3% | 17.82+9.1% | 16.33-30.5% | 23.50+42.8% | 16.46+92.3% | 8.56+68.8% | 5.07+225.0% | 1.56+218.4% | 0.49 |
| Total Current Assets | 306.33-0.3% | 307.39-8.6% | 336.29-22.7% | 434.98-17.2% | 525.18+16.6% | 450.45+267.4% | 122.61-13.7% | 142.08-46.4% | 265.17 |
| Net Property, Plant & Equipment | 1.30-90.3% | 13.43-16.7% | 16.13+57.2% | 10.26-8.6% | 11.23+135.9% | 4.76-24.1% | 6.27+307.1% | 1.54+35.1% | 1.14 |
| Total Investments and Advances | 0.00 | 0.00-100.0% | 1.65-78.3% | 7.61-81.5% | 41.24-13.9% | 47.91 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | 14.36+5.7% | 13.58+33.4% | 10.18+20.8% | 8.43+26.4% | 6.67+23.5% | 5.40 |
| Deferred Tax Assets | 0.79 | - | 0.00-100.0% | 37.10+42.4% | 26.05 | - | - | - | - |
| Other Assets | 15.52+1237.9% | 1.16+63.4% | 0.71-21.1% | 0.90+30.4% | 0.69+72.5% | 0.40+8.1% | 0.37+42.3% | 0.26+13.0% | 0.23 |
| Total Assets | 323.94+0.6% | 321.98-9.2% | 354.78-27.7% | 490.86-20.6% | 617.97+20.3% | 513.69+273.1% | 137.68-8.6% | 150.56-44.6% | 271.95 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.54+158.4% | 1.37-6.8% | 1.47+33.6% | 1.10-85.5% | 7.60+64.1% | 4.63+309.7% | 1.13 | 0.00 | 0.00 |
| Accounts Payable | 9.18-49.1% | 18.03+15.8% | 15.57+26.1% | 12.35+2.2% | 12.08 | 0.00-100.0% | 3.33-50.7% | 6.75-11.4% | 7.62 |
| Income Tax Payable | - | - | - | 0.00-100.0% | 3.75+2400.0% | 0.15+200.0% | 0.05-73.7% | 0.19+18.8% | 0.16 |
| Other Current Liabilities | 57.45-5.9% | 61.07+20.6% | 50.63-26.1% | 68.49+35.6% | 50.50+41.7% | 35.65+131.0% | 15.43+0.1% | 15.41+20.7% | 12.77 |
| Total Current Liabilities | 70.16-12.8% | 80.47+18.9% | 67.67-17.4% | 81.94+10.8% | 73.94+82.8% | 40.44+102.8% | 19.94-10.8% | 22.35+8.8% | 20.55 |
| Long Term Debt | 436.01+258.5% | 121.63-1.0% | 122.91+5.7% | 116.28-12.0% | 132.09+19.6% | 110.45+2732.1% | 3.90 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 3.65+3.1% | 3.54+32.1% | 2.68+92.8% | 1.39+28.7% | 1.08 |
| Deferred Tax Liabilities | 0.79 | - | - | - | - | - | - | - | - |
| Other Liabilities | 2.81-99.1% | 322.53+3.2% | 312.45+46.6% | 213.19-12.0% | 242.20+919.4% | 23.76 | 0.00-100.0% | 0.57-50.9% | 1.16 |
| Total Liabilities | 509.77-2.8% | 524.62+4.3% | 503.03+22.3% | 411.41-9.0% | 451.88+153.6% | 178.19+571.7% | 26.53+9.1% | 24.32+6.8% | 22.78 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -185.83 | -202.64 | -148.25-286.6% | 79.45-52.2% | 166.09-50.5% | 335.50+201.8% | 111.16-11.9% | 126.24-49.3% | 249.17 |
| Total Shareholders Equity | -185.83 | -202.64 | -148.25-286.6% | 79.45-52.2% | 166.09-50.5% | 335.50+201.8% | 111.16-11.9% | 126.24-49.3% | 249.17 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -185.83 | -202.64 | -148.25-286.6% | 79.45-52.2% | 166.09-50.5% | 335.50+201.8% | 111.16-11.9% | 126.24-49.3% | 249.17 |
| Total Liabilities & Stockholders Equity | 323.94+0.6% | 321.98-9.2% | 354.78-27.7% | 490.86-20.6% | 617.97+20.3% | 513.69+273.1% | 137.68-8.6% | 150.56-44.6% | 271.95 |
| Book Value Per Share per share | -1.48 | -2.05 | -1.80-281.8% | 0.99-54.2% | 2.16-50.6% | 4.37+163.3% | 1.66-9.3% | 1.83-49.4% | 3.62 |
| Tangible Book Value Per Share per share | -1.48 | -2.05 | -1.80-281.8% | 0.99-50.3% | 1.99-53.1% | 4.24+175.3% | 1.54-11.5% | 1.74-50.8% | 3.54 |
| Full-Time Employees people | 193-27.2% | 265+63.6% | 162-48.9% | 317+1.6% | 312+50.0% | 208+63.8% | 127 | - | - |
| Price to Book Ratio ratio | -0.72 | -1.12 | -2.47 | 2.82 | 9.34 | 7.32 | 6.52 | - | - |
| Return on Assets % | -44.16 | -46.65 | -54.31 | -28.34 | -40.65 | -75.62 | -80.82 | -58.32 | - |
| Return on Equity % | - | - | - | -127.99 | -91.72 | -110.28 | -98.13 | -65.65 | - |
| Return on Invested Capital % | -57.01 | - | - | -80.28 | -77.14 | -55.23 | -101.24 | -97.51 | -36.07 |
| Quick Ratio ratio | 4.31 | 3.59 | 4.73 | 5.16 | 6.95 | 11.14 | 6.15 | 6.36 | 12.91 |
| Current Ratio ratio | 4.37 | 3.82 | 4.97 | 5.31 | 7.10 | 11.14 | 6.15 | 6.36 | 12.91 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -78.34 | -142.62 | -157.85 | -240.05 | -157.13 | -230.03 | -246.29 | -116.48 | -123.10 |
| Depreciation | - | 1.88-42.7% | 3.28+0.3% | 3.27+36.8% | 2.39-9.1% | 2.63+33.5% | 1.97+19.4% | 1.65+223.5% | 0.51 |
| Other Funds (Non Cash) | -2.00 | 24.93-7.4% | 26.91-26.7% | 36.73-45.0% | 66.78+64.6% | 40.56-35.9% | 63.23+5446.5% | 1.14+54.1% | 0.74 |
| Funds from Operations | -80.25 | -115.82 | -127.66 | -162.96 | -89.59 | -212.89 | -181.09 | -113.70 | -121.84 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -18.76 | -25.36-762.1% | 3.83-91.3% | 44.27 | -48.73 | -20.49-265.8% | 12.36 | -7.88-1741.7% | 0.48 |
| Cash from Operating Activities | -99.01 | -141.17 | -123.84 | -118.69 | -138.31 | -233.38 | -168.73 | -121.58 | -121.36 |
| Capital Expenditures | -0.03 | -0.26 | -0.87 | -3.22 | -0.69 | -6.38 | -2.81 | -2.15 | -2.47 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.68 | 0.66 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.30 | -0.02 | -0.10 | -0.04 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.66 | 0.40 | -0.87 | -3.22 | -0.69 | -6.67 | -2.83 | -2.25 | -2.51 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 59.22 | 152.46+55.2% | 98.22+12655.8% | 0.77-87.0% | 5.91+657.7% | 0.78-99.8% | 433.21+326.8% | 101.51 | -0.02 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | -0.22 | 0.00 | 0.00 | -0.14 | -0.02 |
| Sale of Common Pref Stock | 59.22 | 152.46+55.2% | 98.22+12655.8% | 0.77-87.4% | 6.13+685.9% | 0.78-99.8% | 433.21+326.1% | 101.66 | 0.00 |
| Proceedsfrom Stock Options | 44.38 | 86.55+41.7% | 61.06 | 0.00-100.0% | 6.13 | 0.00-100.0% | 433.16+326.1% | 101.66 | 0.00 |
| Issuance or Reduction of Debt, Net | -1.47 | 0.00 | 0.00 | 0.00 | -5.49-111.1% | 49.59-21.2% | 62.90 | - | 0.00 |
| Change in Long Term Debt | -1.47 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
| Reduction of Long Term Debt | -1.47 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
| Net Financing Active Other Cash Flow | -2.28 | -1.51 | -1.16-101.6% | 73.10 | -1.32-100.6% | 218.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -2.28 | -1.51 | -1.16 | 0.00 | -1.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 55.48 | 150.95+55.5% | 97.05+31.4% | 73.88 | -0.90-100.3% | 267.39-46.0% | 494.97+392.5% | 100.51 | -0.02 |
| Exchange Rate Effect | 0.05 | 0.31 | -0.08-144.4% | 0.18 | -0.21-2200.0% | 0.01-95.8% | 0.24+300.0% | 0.06 | -0.05 |
| Net Change in Cash | -42.82 | 10.47 | -27.73 | -47.84 | -140.10-612.2% | 27.35-91.5% | 323.64 | -23.26 | -123.95 |
| Free Cash Flow | -99.03 | -141.44 | -124.70 | -121.90 | -139.00 | -236.81 | -169.53 | -121.94 | -122.31 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00-100.0% | 37.10 | -1.62 | -26.05 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 189.20-19.4% | 219.11-17.2% | 231.01+18.6% | 261.34+4.2% | 234.74-14.4% | 264.56-11.8% | 194.70-16.9% | 250.87-10.0% |
| Short Term Receivables | 28.42+24.0% | 28.04+7.1% | 31.05-2.2% | 29.12+43.3% | 22.92-4.6% | 26.18+14.5% | 31.76+37.0% | 20.32-19.3% |
| Inventories | 5.63-68.8% | 4.93-72.2% | 4.78-72.6% | 4.18-77.3% | 18.04+12.3% | 17.76+16.9% | 17.45+9.1% | 18.39+13.7% |
| Other Current Assets | 15.33+33.9% | 9.63-6.0% | 9.94-29.4% | 11.70-34.3% | 11.45-38.5% | 10.25-40.3% | 14.08-15.9% | 17.82+9.1% |
| Total Current Assets | 238.58-16.9% | 261.71-17.9% | 276.77+7.3% | 306.33-0.3% | 287.15-13.8% | 318.75-10.3% | 257.99-11.1% | 307.39-8.6% |
| Net Property, Plant & Equipment | 1.00-28.1% | 1.10-26.2% | 1.20-91.0% | 1.30-90.3% | 1.39-90.7% | 1.49-90.2% | 13.39-15.5% | 13.43-16.7% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Deferred Tax Assets | - | - | - | 0.79 | - | - | - | - |
| Other Assets | 16.28+1234.4% | 16.57+1155.3% | 13.53+1066.4% | 15.52+1237.9% | 1.22+4.3% | 1.32+33.3% | 1.16+17.2% | 1.16+63.4% |
| Total Assets | 255.86-11.7% | 279.38-13.1% | 291.50+7.0% | 323.94+0.6% | 289.76-17.0% | 321.56-13.5% | 272.54-11.5% | 321.98-9.2% |
| Short Term Debt Incl. Current Port. of LT Debt | 7.80+738.7% | 6.18+245.3% | 4.63-44.1% | 3.54+158.4% | 0.93-37.2% | 1.79+26.1% | 8.29+479.7% | 1.37-6.8% |
| Accounts Payable | 5.58-31.3% | 12.76+32.6% | 5.29-66.1% | 9.18-49.1% | 8.12-43.5% | 9.62-10.2% | 15.59+8.9% | 18.03+15.8% |
| Other Current Liabilities | 64.74+22.2% | 67.39+26.7% | 57.70+70.2% | 57.45-5.9% | 52.99+2.2% | 53.19+16.9% | 33.91-28.2% | 61.07+20.6% |
| Total Current Liabilities | 78.12+25.9% | 86.33+33.6% | 67.63+17.0% | 70.16-12.8% | 62.04-8.3% | 64.60+12.1% | 57.79-8.2% | 80.47+18.9% |
| Long Term Debt | 108.30-76.3% | 111.38-75.2% | 112.03-75.0% | 436.01+258.5% | 456.50+270.9% | 448.98+265.1% | 448.52+264.9% | 121.63-1.0% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 0.79 | - | - | - | - |
| Other Liabilities | 318.61+3293.1% | 309.87+4221.8% | 328.21+7275.5% | 2.81-99.1% | 9.39-97.2% | 7.17-97.8% | 4.45-98.6% | 322.53+3.2% |
| Total Liabilities | 505.04-4.3% | 507.58-2.5% | 507.87-0.6% | 509.77-2.8% | 527.94+1.3% | 520.75+3.4% | 510.76+1.7% | 524.62+4.3% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -249.17 | -228.21 | -216.38 | -185.83 | -238.18 | -199.18 | -238.22 | -202.64 |
| Total Shareholders Equity | -249.17 | -228.21 | -216.38 | -185.83 | -238.18 | -199.18 | -238.22 | -202.64 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -249.17 | -228.21 | -216.38 | -185.83 | -238.18 | -199.18 | -238.22 | -202.64 |
| Total Liabilities & Stockholders Equity | 255.86-11.7% | 279.38-13.1% | 291.50+7.0% | 323.94+0.6% | 289.76-17.0% | 321.56-13.5% | 272.54-11.5% | 321.98-9.2% |
| Book Value Per Share per share | -1.95 | -1.79 | -1.70 | -1.48 | -2.11 | -1.77 | -2.40 | -2.05 |
| Tangible Book Value Per Share per share | -1.95 | -1.79 | -1.70 | -1.48 | -2.11 | -1.77 | -2.40 | -2.05 |
| Full-Time Employees people | - | - | - | 193-27.2% | - | - | - | 265+63.6% |
| Price to Book Ratio ratio | -0.72 | -0.63 | -2.54 | -1.67 | -2.26 | -1.12 | -0.69 | -1.12 |
| Return on Assets % | -29.78 | -32.25 | -48.57 | -44.16 | -52.26 | -49.02 | -51.62 | -46.65 |
| Return on Invested Capital % | - | - | - | -2.56 | -18.76 | -22.68 | -18.36 | - |
| Quick Ratio ratio | 2.98 | 2.97 | 4.02 | 4.31 | 4.34 | 4.66 | 4.16 | 3.59 |
| Current Ratio ratio | 3.05 | 3.03 | 4.09 | 4.37 | 4.63 | 4.93 | 4.46 | 3.82 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -23.99 | -16.34 | -32.97 | -5.04 | -43.84 | -60.71 | -38.60 | -29.07 |
| Depreciation | - | - | 0.11-86.3% | 0.10-86.8% | 0.14-83.9% | 0.91+12.3% | 0.80-4.8% | 0.76-24.0% |
| Other Funds (Non Cash) | 11.53-0.6% | -7.47-142.6% | 8.15-25.8% | -14.22 | 11.60+11.4% | 17.54+138.0% | 10.98-5.3% | -2.35 |
| Funds from Operations | -12.45 | -23.92 | -24.71 | -19.17 | -32.10 | -42.26 | -26.82 | -30.66 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -14.18-4989.7% | 12.30-16.6% | -5.01 | -11.87-216.9% | 0.29-96.5% | 14.74 | -29.52 | 10.15+1.4% |
| Cash from Operating Activities | -26.64 | -11.62 | -29.71 | -31.03 | -31.81 | -27.52 | -56.33 | -20.51 |
| Capital Expenditures | 0.00 | 0.00 | -0.03 | 0.00 | -0.00 | -0.01 | -0.26 | -0.08 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | -0.03 | 0.69 | -0.00 | -0.01 | -0.26 | -0.08 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.60-205.3% | 0.12-99.9% | 0.19-29.6% | 59.52 | 0.57-76.9% | 98.06+1.0% | 0.27-25.0% | -1.33-270.5% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | -0.60-205.3% | 0.12-99.9% | 0.19-29.6% | 59.52 | 0.57-76.9% | 98.06+1.0% | 0.27-25.0% | -1.33-270.5% |
| Proceedsfrom Stock Options | -0.60-101.3% | 0.00 | -0.02 | 45.00-26.6% | 44.94 | 0.00 | 0.00 | 61.29 |
| Issuance or Reduction of Debt, Net | -1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.02 | -0.21 | -0.77 | -1.31 | -0.00 | -0.26 | 0.00 | -1.17 |
| Other Financing Activities Uses | 0.02 | -0.21 | -0.77 | -1.31 | -0.00 | -0.26 | 0.00 | -1.17 |
| Cash from Financing Activities | -2.05-459.6% | -0.10-100.1% | -0.58-314.8% | 58.21 | 0.57-76.9% | 97.80+0.7% | 0.27-25.0% | -2.49-339.4% |
| Exchange Rate Effect | 0.08+700.0% | 0.00-100.0% | -0.00-100.0% | -0.03 | 0.01-96.7% | 0.18+1700.0% | 0.16 | -0.35-333.3% |
| Net Change in Cash | -28.61 | -11.71-116.6% | -30.33 | 27.83 | -31.23 | 70.44+7.6% | -56.17 | -23.43 |
| Free Cash Flow | -26.64 | -11.62 | -29.74 | -31.03 | -31.81 | -27.53 | -56.60 | -20.59 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| License Revenues | - | 5.00 | - | 6.1% |
| Product | 69.28 | 73.55 | +6.2% | 90.4% |
| Royalty | 1.56 | 2.81 | +80.2% | 3.4% |
| Total | 70.84 | 81.36 | +14.9% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| EMEA | 1.56 | 7.81 | +401.3% | 9.6% |
| United States | 69.28 | 73.55 | +6.2% | 90.4% |
| Total | 70.84 | 81.36 | +14.9% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 6.49% | 6.4M | 99.0M | 1.55M |
| 2026-10-15 | 6.40% | 6.3M | 99.0M | 1.53M |
| 2026-09-30 | 6.96% | 6.9M | 99.0M | 1.40M |
| 2026-09-15 | 5.44% | 5.4M | 99.0M | 1.42M |
| 2026-08-31 | 6.35% | 6.3M | 98.9M | 2.00M |
| 2026-08-14 | 6.24% | 6.2M | 98.9M | 1.78M |
| 2026-07-31 | 5.24% | 5.1M | 97.3M | 1.86M |
| 2026-07-15 | 5.69% | 5.5M | 97.3M | 1.90M |
| 2026-06-30 | 6.16% | 6.0M | 97.3M | 1.81M |
| 2026-06-15 | 6.16% | 6.0M | 97.5M | 1.63M |
| 2026-05-29 | 6.22% | 6.1M | 97.5M | 999.34K |
| 2026-05-15 | 5.87% | 5.7M | 97.9M | 1.02M |
| 2026-04-30 | 5.84% | 5.5M | 93.7M | 880.42K |
| 2026-04-15 | 5.49% | 5.1M | 93.7M | 848.60K |
| 2026-03-31 | 5.29% | 4.9M | 92.7M | 815.85K |
| 2026-03-13 | 4.63% | 4.3M | 92.7M | 901.86K |
| 2026-02-27 | 4.54% | 4.1M | 90.4M | 1.14M |
| 2026-02-13 | 4.83% | 4.4M | 90.4M | 1.11M |
| 2026-01-30 | 4.34% | 4.4M | 101.9M | 1.14M |
| 2026-01-15 | 3.76% | 3.8M | 101.9M | 1.13M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 0.10 | 0.05 | 1010.0% | 247 | 0.00 | 0.692 | -0.050 | 0.001 |
| call | 5.00 | 0.00 | 0.05 | 0.00 | 640.5% | 0.00 | 0.00 | 0.196 | -0.024 | 0.001 |
| call | 7.50 | 0.00 | 3.80 | 0.00 | 664.8% | 0.00 | 0.00 | 0.108 | -0.016 | 0.000 |
| put | 2.50 | 0.00 | 4.80 | 1.15 | 0.0% | 2.00 | 0.00 | -0.743 | -0.017 | 0.001 |
| put | 5.00 | 1.05 | 5.90 | 0.00 | 0.0% | 0.00 | 0.00 | -0.879 | -0.014 | 0.000 |
| put | 7.50 | 3.50 | 8.40 | 0.00 | 0.0% | 0.00 | 0.00 | -0.892 | -0.015 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | S-3 | Registration statement for specified transactions by certain issuers including face-amount certificate companies | SEC | |
| 2026-11-09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-11-04 | 8-K | Current report | 2026-11-04 | SEC |
| 2026-11-03 | S-4 | Registration statement for securities to be issued in business combination transactions | SEC | |
| 2026-10-29 | SCHEDULE 13G | SEC | ||
| 2026-10-13 | 8-K | Current report | 2026-10-07 | SEC |
| 2026-08-14 | SCHEDULE 13G | SEC | ||
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-07-27 | SCHEDULE 13G | SEC | ||
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-02 | 8-K | Current report | 2026-06-30 | SEC |
| 2026-06-24 | 8-K | Current report | 2026-06-24 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-03 | 8-K | Current report | 2026-06-03 | SEC |
| 2026-06-02 | 8-K | Current report | 2026-06-01 | SEC |
| 2026-05-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-04 | 8-K | Current report | 2026-05-04 | SEC |
| 2026-04-24 | SCHEDULE 13G/A | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 18.19M | 4 |
| 2026-03 | 0 | 0 | 1.44M | 2 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Nantahala Capital Management, LLC | 19.38% |
| Redmile Group, LLC | 9.06% |
| TCG Crossover Management, LLC | 8.96% |
| Prosight Management, LP | 6.15% |
| BlackRock, Inc. | 5.52% |
| AIGH Capital Management LLC | 3.39% |
| Point72 Asset Management, L.P. | 2.87% |
| MORGAN STANLEY | 2.40% |
| MILLENNIUM MANAGEMENT LLC | 2.28% |
| CITADEL ADVISORS LLC | 1.61% |
Funds
| Fund | % owned |
|---|---|
| iShares Russell 2000 ETF | 2.15% |
| Fidelity Small Cap Index Fund | 0.91% |
| Oaktree Diversified Income Fund Inc. | 0.89% |
| iShares Russell 2000 Value ETF | 0.58% |
| iShares Biotechnology ETF | 0.53% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.48% |
| iShares Micro-Cap ETF | 0.28% |
| VANGUARD U.S. MOMENTUM FACTOR ETF | 0.25% |
| Schwab Small-Cap Index Fund | 0.20% |
| iShares Russell 2000 Growth ETF | 0.16% |
OakChart. ADCT. Cached 15 minutes. Terms